Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Decoding the Mystery of Blood Cancer: Cause, Diagnosis, and Management

Author(s): Raja Sharma, Satendra Kumar*, Niranjan Kaushik and Bahadur Singh

Volume 21, Issue 1, 2025

Published on: 16 January, 2024

Page: [40 - 53] Pages: 14

DOI: 10.2174/0115733947263279231114111550

Price: $65

Open Access Journals Promotions 2
Abstract

Leukaemia, lymphoma, and myeloma are among the serious and frequently fatal conditions that impact thousands of people each year. Genetics, environmental factors, and medical problems can all affect the risk of developing blood cancer, however, the precise causes are still not entirely known. Fatigue, unexpected weight loss, and frequent infections are examples of common blood cancer symptoms. In the course of the diagnosis process, blood tests, imaging tests, and bone marrow biopsies are frequently combined. Blood cancer therapies include chemotherapy, radiation therapy, stem cell transplant, targeted therapy, and immunotherapy. Supportive care is also important for managing symptoms and improving quality of life. Ongoing research is exploring new treatments and therapies for blood cancer, as well as ways to improve supportive care and personalize treatment plans. Blood cancer patients and their families have severe emotional and psychological effects that must not be ignored. For improving outcomes and raising the general standard of living for people affected by this condition, it is essential to address these needs.

Keywords: Blood cancer, leukemia, lymphoma, myeloma, genetics, environmental factors, medical conditions, symptoms, diagnosis, staging, chemotherapy, radiation therapy, stem cell transplant, targeted therapy, immunotherapy, supportive care, research, clinical trials, personalized medicine, emotional impact, psychological impact.

« Previous Next »
Graphical Abstract

[1]
Lidder PG, Sanders G, Whitehead E, et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Ann R Coll Surg Engl 2007; 89(4): 418-21.
[http://dx.doi.org/10.1308/003588407X183364] [PMID: 17535624]
[2]
Dietrich S, Oleś M, Lu J, et al. Drug-perturbation-based stratification of blood cancer. J Clin Invest 2017; 128(1): 427-45.
[http://dx.doi.org/10.1172/JCI93801] [PMID: 29227286]
[3]
Melchionda F, Spreafico F, Ciceri S, et al. A novel WT1 mutation in familial wilms tumor. Pediatr Blood Cancer 2013; 60(8): 1388-9.
[http://dx.doi.org/10.1002/pbc.24539] [PMID: 23554000]
[4]
Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: An update. Blood Cancer J 2011; 1(4): e16.
[http://dx.doi.org/10.1038/bcj.2011.14] [PMID: 22829137]
[5]
Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007; 2007(1): CD001216.
[6]
Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: Where did we start, where are we now, and the future. Blood Cancer J 2015; 5(4): e304.
[http://dx.doi.org/10.1038/bcj.2015.25] [PMID: 25885425]
[7]
Cencic R, Robert F, Galicia-Vázquez G, et al. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J 2013; 3(7): e128.
[http://dx.doi.org/10.1038/bcj.2013.25] [PMID: 23872707]
[8]
Madanan M, Venugopal A, Velayudhan NC. Applying an optimal feature ranking and selection algorithm and random forest classifier algorithm along with k-fold cross validation for classification of blood cancer cells. Eur J Mol Clin Med 2020; 7(11): 774-89.
[9]
Tagde A, Singh H, Kang MH, Reynolds CP. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J 2014; 4(7): e229.
[http://dx.doi.org/10.1038/bcj.2014.45] [PMID: 25036800]
[10]
Costa-Silva TA, Costa IM, Biasoto HP, et al. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Rev 2020; 43: 100651.
[http://dx.doi.org/10.1016/j.blre.2020.100651] [PMID: 32014342]
[11]
Landgren O, Graubard BI, Kumar S, et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: A population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J 2017; 7(10): e618.
[http://dx.doi.org/10.1038/bcj.2017.97] [PMID: 29053158]
[12]
Hou H-A, Chou W-C, Kuo Y-Y, et al. TP53 mutations in de novo acute myeloid leukemia patients: Longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J 2015; 5(7): e331.
[http://dx.doi.org/10.1038/bcj.2015.59] [PMID: 26230955]
[13]
Trudel S, Lendvai N, Popat R, et al. Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study. Blood Cancer J 2019; 9(4): 37.
[http://dx.doi.org/10.1038/s41408-019-0196-6] [PMID: 30894515]
[14]
Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: Their changes associated with human cancer. Biochim Biophys Acta, Gen Subj 1999; 1473(1): 247-66.
[http://dx.doi.org/10.1016/S0304-4165(99)00183-X] [PMID: 10580143]
[15]
Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127(S5): S5-S16.
[http://dx.doi.org/10.1053/j.gastro.2004.09.011] [PMID: 15508102]
[16]
Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J 2019; 9(4): 44.
[http://dx.doi.org/10.1038/s41408-019-0205-9] [PMID: 30962422]
[17]
Kong Y, Zhang J, Claxton DF, et al. PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J 2015; 5(7): e330.
[http://dx.doi.org/10.1038/bcj.2015.58] [PMID: 26230954]
[18]
Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J 2015; 5(4): e306.
[http://dx.doi.org/10.1038/bcj.2015.32] [PMID: 25885426]
[19]
Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 2015; 5(3): e296.
[http://dx.doi.org/10.1038/bcj.2015.20] [PMID: 25794132]
[20]
Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V. MTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014; 345(6204): 1250684.
[21]
Meenaghan T, Dowling M, Kelly M. Acute leukaemia: Making sense of a complex blood cancer. Br J Nurs 2012; 21(2): 76-78-83.
[22]
Hasselbalch HC, Skov V, Kjær L, Sørensen TL, Ellervik C, Wienecke T. Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives. J Neuroinflammation 2020; 17(1): 248.
[http://dx.doi.org/10.1186/s12974-020-01877-3] [PMID: 32829706]
[23]
Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985; 254(14): 1932-7.
[http://dx.doi.org/10.1001/jama.1985.03360140090031] [PMID: 4046122]
[24]
Gile J, Ruan G, Abeykoon J, McMahon MM, Witzig T. Magnesium: The overlooked electrolyte in blood cancers? Blood Rev 2020; 44: 100676.
[http://dx.doi.org/10.1016/j.blre.2020.100676] [PMID: 32229066]
[25]
Cunha Júnior AD, Pericole FV, Carvalheira JBC. Metformin and blood cancers. Clinics 2018; 73(S1): e412s.
[http://dx.doi.org/10.6061/clinics/2018/e412s] [PMID: 30208162]
[26]
Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP. Risk factors for arterial versus venous thrombosis in polycythemia vera: A single center experience in 587 patients/692/499/692/699/1541/1990/2331 article. Blood Cancer J 2017; 7(12): 662.
[27]
Peisch SF, Van Blarigan EL, Chan JM, Stampfer MJ, Kenfield SA. Prostate cancer progression and mortality: A review of diet and lifestyle factors. World J Urol 2017; 35(6): 867-74.
[http://dx.doi.org/10.1007/s00345-016-1914-3] [PMID: 27518576]
[28]
Delebarre M, Dessein R, Lagrée M, et al. Differential risk of severe infection in febrile neutropenia among children with blood cancer or solid tumor. J Infect 2019; 79(2): 95-100.
[http://dx.doi.org/10.1016/j.jinf.2019.06.008] [PMID: 31228471]
[29]
Matthews DC. Inherited disorders of platelet function. Pediatr Clin North Am 2013; 60(6): 1475-88.
[http://dx.doi.org/10.1016/j.pcl.2013.08.004] [PMID: 24237983]
[30]
Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 2007; 67(4): 1407-10.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-2149] [PMID: 17308075]
[31]
Rafei H, DiNardo CD. Hereditary myeloid malignancies. Best Pract Res Clin Haematol 2019; 32(2): 163-76.
[http://dx.doi.org/10.1016/j.beha.2019.05.001] [PMID: 31203998]
[32]
Keel SB, Scott A, Bonilla MS, Ho PA, Gulsuner S, Pritchard CC, et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica 2016; 101(11): 1343.
[http://dx.doi.org/10.3324/haematol.2016.149476]
[33]
Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood 2016; 127(11): 1387-97.
[http://dx.doi.org/10.1182/blood-2015-09-669937] [PMID: 26702063]
[34]
Wen J, Rusch M, Brady SW, et al. The landscape of coding RNA editing events in pediatric cancer. BMC Cancer 2021; 21(1): 1233.
[http://dx.doi.org/10.1186/s12885-021-08956-5] [PMID: 34789196]
[35]
Buonocore F, Kühnen P, Suntharalingham JP, et al. Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans. J Clin Invest 2017; 127(5): 1700-13.
[http://dx.doi.org/10.1172/JCI91913] [PMID: 28346228]
[36]
Churpek JE, Godley LA. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood 2016; 128(14): 1800-13.
[http://dx.doi.org/10.1182/blood-2016-05-670240] [PMID: 27471235]
[37]
Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 2015; 27(5): 658-70.
[http://dx.doi.org/10.1016/j.ccell.2015.03.017] [PMID: 25920683]
[38]
Mangaonkar AA, Patnaik MM. Hereditary predisposition to hematopoietic neoplasms. Mayo Clin Proc 2020; 95(7): 1482-98.
[http://dx.doi.org/10.1016/j.mayocp.2019.12.013] [PMID: 32571604]
[39]
Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332(26): 1744-8.
[http://dx.doi.org/10.1056/NEJM199506293322603] [PMID: 7760890]
[40]
Yang M. A current global view of environmental and occupational cancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2011; 29(3): 223-49.
[http://dx.doi.org/10.1080/10590501.2011.601848]
[41]
Jee SH, Park JY, Kim HS, Lee TY, Samet JM. White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans. Am J Epidemiol 2005; 162(11): 1062-9.
[http://dx.doi.org/10.1093/aje/kwi326] [PMID: 16221804]
[42]
Terpos E, Christoulas D, Kastritis E, et al. High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. Blood Cancer J 2016; 6(10): e482.
[http://dx.doi.org/10.1038/bcj.2016.90] [PMID: 27716740]
[43]
Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers 2021; 13(9): 2025.
[http://dx.doi.org/10.3390/cancers13092025] [PMID: 33922197]
[44]
Breen S, Kofoed S, Ritchie D, et al. Remote real-time monitoring for chemotherapy side-effects in patients with blood cancers. Collegian 2017; 24(6): 541-9.
[http://dx.doi.org/10.1016/j.colegn.2016.10.009]
[45]
Hippisley-Cox J, Coupland C. Symptoms and risk factors to identify men with suspected cancer in primary care: Derivation and validation of an algorithm. Br J Gen Pract 2013; 63(606): e1-e10.
[http://dx.doi.org/10.3399/bjgp13X660724] [PMID: 23336443]
[46]
Hippisley-Cox J, Coupland C. Symptoms and risk factors to identify women with suspected cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2013; 63(606): e11-21.
[http://dx.doi.org/10.3399/bjgp13X660733] [PMID: 23336450]
[47]
Aryal M, Vykhodtseva N, Zhang YZ, Park J, McDannold N. Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood–tumor and blood–brain barriers improve outcomes in a rat glioma model. J Control Release 2013; 169(1-2): 103-11.
[http://dx.doi.org/10.1016/j.jconrel.2013.04.007] [PMID: 23603615]
[48]
Krukemeyer MG, Krenn V, Jakobs M, Wagner W. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment. J Surg Res 2012; 175(1): 35-43.
[http://dx.doi.org/10.1016/j.jss.2011.01.060] [PMID: 21470623]
[49]
Gonçalves MC, de Oliveira CRGCM, Sandes AF, et al. Core needle biopsy in lymphoma diagnosis. Am J Surg Pathol 2023; 47(1): 111-23.
[http://dx.doi.org/10.1097/PAS.0000000000001991] [PMID: 36395467]
[50]
Carrara S, Rahal D, Khalaf K, et al. Diagnostic accuracy and safety of EUS-guided end-cutting fine-needle biopsy needles for tissue sampling of abdominal and mediastinal lymphadenopathies: A prospective multicenter series. Gastrointest Endosc 2023; 98(2): 191-8.
[http://dx.doi.org/10.1016/j.gie.2023.03.018] [PMID: 36990125]
[51]
Guan C, Wu M, Ye J, et al. Macroscopic on site quality evaluation of biopsy specimens to improve the diagnostic accuracy of endoscopic ultrasound guided fine needle aspiration using a 22 gauge needle for solid lesions: A single center retrospective study. Exp Ther Med 2023; 26(1): 338.
[http://dx.doi.org/10.3892/etm.2023.12037] [PMID: 37383379]
[52]
Gómez GE, Cano CR, Burgos J, et al. ProsTAV, a novel blood‐based test for biopsy decision management in significant prostate cancer. Prostate 2023; 83(14): 1323-31.
[http://dx.doi.org/10.1002/pros.24594] [PMID: 37409738]
[53]
Esteva M, Leiva A, Ramos M, et al. Factors related with symptom duration until diagnosis and treatment of symptomatic colorectal cancer. BMC Cancer 2013; 13(1): 87.
[http://dx.doi.org/10.1186/1471-2407-13-87] [PMID: 23432789]
[54]
Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13(1): 47-58.
[http://dx.doi.org/10.1021/bc010021y] [PMID: 11792178]
[55]
Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically meaningful use of blood tumor markers in oncology. BioMed Res Int 2016; 2016: 9795269.
[http://dx.doi.org/10.1155/2016/9795269]
[56]
Rian B, Ruker JD, Oshe M, Alpaz T, Esta EJR, Eng IP. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031-7.
[57]
Saritha M, Prakash BB, Sukesh K, Shrinivas B. Detection of blood cancer in microscopic images of human blood samples: A review. International Conference on Electrical, Electronics, and Optimization Techniques, ICEEOT. 2016; pp. 596-600.
[http://dx.doi.org/10.1109/ICEEOT.2016.7754751]
[58]
Melchionda F, Oncology P, Spreafico F, Unit PO, Hemato-oncology P, Ciceri S. Letter to the editor a novel WT1 Mutation in FLamilial wilms tumor. Pediatr Blood Cancer 2013; (February): 1388-9.
[http://dx.doi.org/10.1002/pbc.24539] [PMID: 23554000]
[59]
Watase C, Shiino S, Shimoi T, et al. Breast cancer brain metastasis—overview of disease state, treatment options and future perspectives. Cancers 2021; 13(5): 1078.
[http://dx.doi.org/10.3390/cancers13051078] [PMID: 33802424]
[60]
Adams DM, Ricci KW. Vascular anomalies. Hematol Oncol Clin North Am 2019; 33(3): 455-70.
[http://dx.doi.org/10.1016/j.hoc.2019.01.011] [PMID: 31030813]
[61]
Tan LL, Lyon AR. Role of biomarkers in prediction of cardiotoxicity during cancer treatment. Curr Treat Options Cardiovasc Med 2018; 20(7): 55.
[http://dx.doi.org/10.1007/s11936-018-0641-z] [PMID: 29923056]
[62]
Naeem N, Reed MD, Creger RJ, Youngner SJ, Lazarus HM. Transfer of the hematopoietic stem cell transplant patient to the intensive care unit: Does it really matter? Bone Marrow Transplant 2005; 37: 119-33.
[63]
Güneş M, Kılıç R, Patıroğlu T, Ezer U, Kürekçi A. Evaluation of transplanted stem cell dynamic variables in the bone marrow of children with malignancies. J Biomed Allied Res 2023; 5(1): 1-9.
[64]
Grulke N, Albani C, Bailer H. Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30. Bone Marrow Transplant 2011; 47: 473-82.
[65]
Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev 2004; 30(1): 103-17.
[http://dx.doi.org/10.1016/S0305-7372(03)00142-7] [PMID: 14766128]
[66]
Hayden PJ, Keogh F, Conghaile MN, Carroll M, Crowley M, Fitzsimon N. A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase. Bone Marrow Transplant 2004; 34(6): 545-56.
[http://dx.doi.org/10.1038/sj.bmt.1704638]
[67]
Worel N, Biener D, Kalhs P, Mitterbauer M, Keil F, Schulenburg A. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant 2002; 30(9): 619-26.
[http://dx.doi.org/10.1038/sj.bmt.1703677]
[68]
Deininger MWN, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003; 55(3): 401-23.
[http://dx.doi.org/10.1124/pr.55.3.4] [PMID: 12869662]
[69]
Mojtahedi H, Yazdanpanah N, Rezaei N. Chronic myeloid leukemia stem cells: Targeting therapeutic implications. Stem Cell Res Ther 2021; 12(1): 603.
[http://dx.doi.org/10.1186/s13287-021-02659-1] [PMID: 34922630]
[70]
Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 2013; 121(22): 4439-42.
[http://dx.doi.org/10.1182/blood-2013-03-490003] [PMID: 23620577]
[71]
Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6(9): 1018-23.
[http://dx.doi.org/10.1038/79526]
[72]
Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71(6): 907-20.
[http://dx.doi.org/10.1189/jlb.71.6.907] [PMID: 12050175]
[73]
Messerschmidt JL, Prendergast GC, Messerschmidt GL. How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: Helping nonimmunologists decipher recent advances. Oncologist 2016; 21(2): 233-43.
[http://dx.doi.org/10.1634/theoncologist.2015-0282] [PMID: 26834161]
[74]
Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A. Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: Monoclonal antibodies, immune checkpoint inhibitors and CAR T-cell therapies. J Fungi 2021; 7(3): 186.
[75]
Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016; 13(5): 273-90.
[76]
Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current progress in CAR-T cell therapy for hematological malignancies. J Cancer 2021; 12(2): 326.
[77]
Riley RS, Day ES. Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017; 9(4): e1449.
[http://dx.doi.org/10.1002/wnan.1449] [PMID: 28160445]
[78]
McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: A retrospective, multicohort analysis. Lancet Oncol 2018; 19(3): 310-22.
[http://dx.doi.org/10.1016/S1470-2045(18)30078-0] [PMID: 29449192]
[79]
Gao Z, Huang S, Wang S, Tang D, Xu W, Zeng R. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: A systematic review and network meta-analysis. Lancet Reg Health West Pac 2023; 38: 100841.
[http://dx.doi.org/10.1016/j.lanwpc.2023.100841]
[80]
Boons E, Nogueira TC, Dierckx T, et al. XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. Blood Cancer J 2021; 11(2): 27.
[http://dx.doi.org/10.1038/s41408-021-00409-3] [PMID: 33563902]
[81]
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood 2008; 111(12): 5446-56.
[http://dx.doi.org/10.1182/blood-2007-06-093906] [PMID: 18216293]
[82]
Madeddu C, Gramignano G, Astara G, et al. Pathogenesis and treatment options of cancer related anemia: Perspective for a targeted mechanism-based approach. Front Physiol 2018; 9(SEP): 1294.
[http://dx.doi.org/10.3389/fphys.2018.01294] [PMID: 30294279]
[83]
Neumann M, Heesch S, Gökbuget N, et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J 2012; 2(1): e55.
[http://dx.doi.org/10.1038/bcj.2011.49] [PMID: 22829239]
[84]
Olson K, Hanson J, Michaud M. A phase II trial of reiki for the management of pain in advanced cancer patients. J Pain Symptom Manage 2003; 26(5): 990-7.
[http://dx.doi.org/10.1016/S0885-3924(03)00334-8] [PMID: 14585550]
[85]
O’Leary M, Krailo M, Anderson JR, Reaman GH. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin Oncol 2008; 35(5): 484-93.
[http://dx.doi.org/10.1053/j.seminoncol.2008.07.008] [PMID: 18929147]
[86]
Suo Y, Gu Z, Wei X. Advances of in vivo flow cytometry on cancer studies. Cytometry A 2020; 97(1): 15-23.
[http://dx.doi.org/10.1002/cyto.a.23851] [PMID: 31273910]
[87]
Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev 2017; 58: 1-13.
[88]
Spinetta JJ, Jankovic M, Masera G, et al. Optimal care for the child with cancer: A summary statement from the SIOP working committee on psychosocial issues in pediatric oncology. Pediatr Blood Cancer 2009; 52(7): 904-7.
[http://dx.doi.org/10.1002/pbc.21863] [PMID: 19142992]
[89]
Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003; 57(1): 98-104.
[http://dx.doi.org/10.1016/S0360-3016(03)00435-8] [PMID: 12909221]
[90]
Masera G, Jankovic M, Deasy-Spinetta P, et al. SIOP working committee on psychosocial issues in pediatric oncology: Guidelines for school/education. Med Pediatr Oncol 1995; 25(6): 429-30.
[http://dx.doi.org/10.1002/mpo.2950250602] [PMID: 7565303]
[91]
Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol 2016; 22(5): 1745-55.
[http://dx.doi.org/10.3748/wjg.v22.i5.1745] [PMID: 26855534]
[92]
Henckel C, Revette A, Huntington SF, Tulsky JA, Abel GA, Odejide OO. Perspectives regarding hospice services and transfusion access: Focus groups with blood cancer patients and bereaved caregivers. J Pain Symptom Manage 2020; 59(6): 1195-1203.e4.
[http://dx.doi.org/10.1016/j.jpainsymman.2019.12.373] [PMID: 31926969]
[93]
Jankovic M, Spinetta JJ, Masera G, Barr RD. Non-conventional therapies in childhood cancer: guidelines for distinguishing non-harmful from harmful therapies: A report of the SIOP Working Committee on Psychosocial Issues in Pediatric Oncology Klin Padiatr 2004; 216(3): 194-7.
[94]
Kim NK, Park YS, Heo DS, Kim HJ, Kang WK, Suh CI. M.D., Si Young Kim, M.D., Keun Chil Park, M.D., Yoon. 2-4.
[95]
Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther 2019; 4(1): 1-14.
[http://dx.doi.org/10.1038/s41392-019-0099-9]
[96]
Borrescio-Higa F, Valdés N. The psychosocial burden of families with childhood blood cancer. Int J Environ Res Public Health 2022; 19(1): 599.
[http://dx.doi.org/10.3390/ijerph19010599] [PMID: 35010854]
[97]
Glimelius B, Garmo H, Berglund Å, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2011; 11(1): 61-71.
[http://dx.doi.org/10.1038/tpj.2010.10] [PMID: 20177420]
[98]
Giantonio BJ, Levy DE, O’Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB III. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the eastern cooperative oncology group study E2200. Ann Oncol 2006; 17(9): 1399-403.
[http://dx.doi.org/10.1093/annonc/mdl161] [PMID: 16873427]
[99]
Best MG, Sol N, Kooi I, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 2015; 28(5): 666-76.
[http://dx.doi.org/10.1016/j.ccell.2015.09.018] [PMID: 26525104]
[100]
Xiang J, Lv B, Fan S, Zhang Z, Yang H. Deltex E3 Ubiquitin Ligase 3L confers radioresistance in prostate cancer via Akt pathway. Trop J Pharm Res 2020; 19(7): 1397-402.
[101]
Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012; 35(2): 169-78.
[http://dx.doi.org/10.1097/CJI.0b013e318247a4e7] [PMID: 22306905]
[102]
De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92(9): 1644-9.
[http://dx.doi.org/10.1038/sj.bjc.6602573] [PMID: 15856038]

Rights & Permissions Print Cite
Article Metrics
4
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy